Analysis toolkit for evaluation of drug titration practice in acute lymphoblastic leukemia maintenance

被引:0
|
作者
Mungle, Tushar [1 ,2 ]
Mahadevan, Ananya [2 ]
Mukhopadhyay, Jayanta [3 ]
Das Bhattacharya, Sangeeta [1 ]
Saha, Vaskar [2 ,4 ,5 ]
Krishnan, Shekhar [2 ,4 ,5 ]
机构
[1] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India
[2] Tata Med Ctr, Tata Translat Canc Res Ctr, 14 Major Arterial Rd E West, Kolkata 700160, W Bengal, India
[3] Indian Inst Technol Kharagpur, Dept Comp Sci & Engn, Kharagpur 721302, W Bengal, India
[4] Tata Med Ctr, Dept Paediat Haematol & Oncol, Kolkata 700160, W Bengal, India
[5] Univ Manchester, Fac Biol Med Hlth, Sch Med Sci, Div Canc Sci, Manchester M13 9PL, England
关键词
acute lymphoblastic leukemia; maintenance therapy; drug titration; visualization and analysis; protocol compliance; RELAPSE; THERAPY;
D O I
10.1093/jamiaopen/ooae089
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective During the 2-year maintenance treatment phase (MT) of acute lymphoblastic leukemia (ALL), personalized patient-specified titration of oral antimetabolite drug doses is required to ensure maximum tolerated systemic drug exposure. Drug titration is difficult to implement in practice and insufficient systemic drug exposure resulting from inadequate dose titration increases risk of ALL relapse.Materials and Methods We developed an open-source R-based analytical toolkit, including the allMT R package and an interactive web-based R Shiny VIATAMIN application, to evaluate antimetabolite drug titration during MT.Results Evaluation is initiated with basic visualization analysis of drug titration, in both individual patients and patient cohorts. Observations are supplemented with descriptive analyses of hematological toxicity frequency and prescriber compliance rates with protocol drug titration rules. In individual patients, visual and quantitative analyses indicate recurring potentially correctable suboptimal drug titration patterns. In patient cohorts, the toolkit enables evaluation of the impact of interventions to optimize MT drug titration.Discussion Incorporation of the toolkit in a forthcoming clinical decision support system for MT would enable real-time examination and course correction of drug titration practice.Conclusion Future versions will be enhanced to include other variables that influence drug titration practice, including clinical toxicity data and later, pharmacological markers of antimetabolite, adherence, and drug activity. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Many children are cured with modern treatment. Treatment typically lasts 2.5 years, including a critical 2-year maintenance phase where children take oral anti-cancer drugs. To ensure optimal treatment, drug doses during the maintenance phase must be adjusted carefully for each child, a process called drug titration. This requires regular blood tests and close monitoring of treatment history. Drug titration is a challenging task and clinical practitioners currently lack specialized tools to efficiently manage this process. To address this requirement, we have developed open-source tools to help visualize drug titration patterns and identify opportunities to improve titration practice. These tools also help highlight when children may be experiencing difficulties tolerating drug treatment. We anticipate that these tools will enhance patient care during the maintenance treatment phase by providing insights into treatment patterns and by highlighting potential areas for improvement in practice.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] ENTEROPATHY COMPLICATING MAINTENANCE THERAPY IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    LEWIS, IJ
    MAINWARING, D
    MARTIN, J
    ARCHIVES OF DISEASE IN CHILDHOOD, 1982, 57 (09) : 663 - 667
  • [22] Decrease of Immunoglobulins in Children on Maintenance Treatment for Acute Lymphoblastic Leukemia
    Vasquez, Marta Rojas
    Black, Karina
    McKillop, Sarah
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S37 - S38
  • [23] TIMING OF MAINTENANCE CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    LEVI, F
    BAILLEUL, F
    MISSET, JL
    REINBERG, A
    MATHE, G
    LANCET, 1986, 1 (8490): : 1160 - 1161
  • [24] Genetic abnormalities and drug resistance in acute lymphoblastic leukemia
    Pui, CH
    Evans, WE
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 1999, 457 : 383 - 389
  • [25] EVALUATION OF LIVER STIFFNESS BY TRANSIENT ELASTOGRAPHY IN CHILDREN DURING AND AFTER MAINTENANCE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA
    Rathe, M.
    Fisker, N.
    Wehner, P. S.
    Christensen, P. B.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 190 - 190
  • [26] EVALUATION OF CORYNEBACTERIUM PARVUM DURING REMISSION MAINTENANCE THERAPY IN PEDIATRIC-PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    LANKFORD, J
    NITSCHKE, R
    WELLS, J
    COX, C
    HUMPHREY, GB
    MEDICAL AND PEDIATRIC ONCOLOGY, 1979, 6 (02): : 101 - 114
  • [27] Analysis of apoptotic and multi-drug resistance phenotype in children with acute lymphoblastic leukemia
    Malinowska, I
    Stelmaszczyk-Emmel, A
    Modzelewska, M
    Nasilowska, B
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 345 - 349
  • [28] Preclinical evaluation of CBP/β-catenin inhibition as a new strategy for drug resistant acute lymphoblastic leukemia
    Kim, Yong-Mi
    Park, Eugene
    Lorentzen, Colin
    De La Torre, Brian
    Hsieh, Yao Te
    Whang, Hannah
    Klemm, Lars
    Nguyen, Cu
    McMillan, Michael
    Teo, Jia-Ling
    Muschen, Markus
    Kahn, Michael
    BLOOD, 2007, 110 (11) : 476A - 477A
  • [29] A DELAY DIFFERENTIAL EQUATIONS MODEL FOR MAINTENANCE THERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Badralexi, Irina
    Halanay, Andrei
    Mghames, Ragheb
    UNIVERSITY POLITEHNICA OF BUCHAREST SCIENTIFIC BULLETIN-SERIES A-APPLIED MATHEMATICS AND PHYSICS, 2020, 82 (03): : 13 - 24
  • [30] Retinitis from cytomegalovirus during maintenance treatment for acute lymphoblastic leukemia
    Kobayashi, Ryoji
    Takanashi, Kuniko
    Suzuki, Daisuke
    Nasu, Takashi
    Uetake, Kimiaki
    Matsumoto, Yoshinori
    PEDIATRICS INTERNATIONAL, 2012, 54 (02) : 288 - 290